Linda Gask is encouraged by the findings of a new high quality RCT (the DRD study), which compares preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in the prevention of depressive relapse or recurrence.
[read the full story...]
Sarah Knowles looks at a next-generation social media-based relapse prevention intervention for youth depression, explored in an Australian qualitative study looking at social networking, safety and clinical benefit.
[read the full story...]
Elwira Lubos summarises a recent review of reviews looking at the evidence for improving outcomes in first-episode psychosis.
[read the full story...]
Andrew Jones summarises a recent systematic review and meta-analysis of alcohol treatment outcome, which identifies a range of personality traits that are associated with relapse.
[read the full story...]
Angharad de Cates explores a recent RCT of a brief psychological intervention to reduce repetition of self-harm in patients admitted to hospital following a suicide attempt.
[read the full story...]
Sarah McDonald asks: What happens after treatment? She summarises a recent systematic review of relapse, remission, and recovery in anorexia nervosa.
[read the full story...]
Alastair Canaway on a recent RCT that looks at the cost-effectiveness of therapist-guided internet-delivered cognitive behaviour therapy for paediatric obsessive–compulsive disorder.
[read the full story...]
Ben Hannigan reports on a recent RCT of the efficacy and cost-effectiveness of a specialist depression service versus usual specialist mental health care to manage persistent depression.
[read the full story...]
Ian Hamilton presents the findings of a recent Cochrane review, which finds that despite the large number of cannabis users seeking treatment, we still know relatively little about the best psychosocial interventions for cannabis use disorder.
[read the full story...]
Tracey Roberts summarises a recent RCT of the efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia.
[read the full story...]
